Biomarkers of ALI/ARDS: Pathogenesis, Discovery, and Relevance to Clinical Trials

David R. Janz; Lorraine B. Ware

doi:10.1055/s-0033-1351124

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2013; 34(04): 537-548
DOI: 10.1055/s-0033-1351124

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Biomarkers of ALI/ARDS: Pathogenesis, Discovery, and Relevance to Clinical Trials

David R. Janz

¹Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee

,

Lorraine B. Ware

¹Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee

²Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee

› Institutsangaben

Abstract

Despite the high incidence and poor prognosis of acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS), it remains challenging to identify patients who are at highest risk of developing these syndromes, differentiate these syndromes from other causes of acute respiratory failure, and accurately prognosticate once the diagnosis is made. The identification and validation of biological markers of ALI has the potential to ameliorate these challenges by facilitating studies of therapies aimed at prevention, identifying patients more accurately that have ALI so they can benefit from evidence-based therapies and enrollment in clinical trials, and determining which patients are unlikely to have a positive outcome to guide therapeutic choices and trials of experimental rescue therapies. This article reviews the current state of biomarker research in ALI/ARDS. New methodologies for identification of novel biomarkers of ALI, including metabolomics, proteomics, gene expression, and genetic studies are also discussed.

Keywords

acute lung injury - biomarker - metabolomics - proteomics - genomics - genetics - acute respiratory distress syndrome

Volltext

Referenzen

References
1 Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342 (18) 1334-1349
2 Rubenfeld GD, Caldwell E, Peabody E , et al. Incidence and outcomes of acute lung injury. N Engl J Med 2005; 353 (16) 1685-1693
3 Biomarkers Definitions Working Group.. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69 (3) 89-95
4 WHO International Programme on Chemical Safety. Biomarkers in risk assessment: validity and validation. 2001. http://www.inchem.org/documents/ehc/ehc/ehc155.htm
5 Eisner MD, Parsons P, Matthay MA, Ware L, Greene K. Acute Respiratory Distress Syndrome Network. Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax 2003; 58 (11) 983-988
6 McClintock DE, Ware LB, Eisner MD, Wickersham N, Thompson BT, Matthay MA. National Heart, Lung, and Blood Institute ARDS Network. Higher urine nitric oxide is associated with improved outcomes in patients with acute lung injury. Am J Respir Crit Care Med 2007; 175 (3) 256-262
7 Suratt BT, Eisner MD, Calfee CS , et al; NHLBI Acute Respiratory Distress Syndrome Network. Plasma granulocyte colony-stimulating factor levels correlate with clinical outcomes in patients with acute lung injury. Crit Care Med 2009; 37 (4) 1322-1328
8 Ware LB, Eisner MD, Thompson BT, Parsons PE, Matthay MA. Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury. Am J Respir Crit Care Med 2004; 170 (7) 766-772
9 Parsons PE, Eisner MD, Thompson BT , et al; NHLBI Acute Respiratory Distress Syndrome Clinical Trials Network. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med 2005; 33 (1) 1-6 , discussion 230–232
10 Ware LB, Fang X, Matthay MA. Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003; 285 (3) L514-L521
11 Parsons PE, Matthay MA, Ware LB, Eisner MD. National Heart, Lung, Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol 2005; 288 (3) L426-L431
12 Calfee CS, Eisner MD, Parsons PE , et al; NHLBI Acute Respiratory Distress Syndrome Clinical Trials Network. Soluble intercellular adhesion molecule-1 and clinical outcomes in patients with acute lung injury. Intensive Care Med 2009; 35 (2) 248-257
13 Calfee CS, Ware LB, Eisner MD , et al; NHLBI ARDS Network. Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax 2008; 63 (12) 1083-1089
14 Ware LB, Fremont RD, Bastarache JA, Calfee CS, Matthay MA. Determining the aetiology of pulmonary oedema by the oedema fluid-to-plasma protein ratio. Eur Respir J 2010; 35 (2) 331-337
15 Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol 2011; 6: 147-163
16 Zimmerman GA, Albertine KH, Carveth HJ , et al. Endothelial activation in ARDS. Chest 1999; 116 (1, Suppl): 18S-24S
17 Staub NC. Pulmonary edema due to increased microvascular permeability. Annu Rev Med 1981; 32: 291-312
18 Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006; 27 (12) 552-558
19 Parikh SM, Mammoto T, Schultz A , et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 2006; 3 (3) e46
20 Fiedler U, Reiss Y, Scharpfenecker M , et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006; 12 (2) 235-239
21 Bhandari V, Choo-Wing R, Lee CG , et al. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med 2006; 12 (11) 1286-1293
22 van der Heijden M, van Nieuw Amerongen GP, Koolwijk P, van Hinsbergh VW, Groeneveld AB. Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients. Thorax 2008; 63 (10) 903-909
23 Gallagher DC, Parikh SM, Balonov K , et al. Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome. Shock 2008; 29 (6) 656-661
24 Calfee CS, Gallagher D, Abbott J, Thompson BT, Matthay MA. NHLBI ARDS Network. Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance. Crit Care Med 2012; 40 (6) 1731-1737
25 Langer HF, Chavakis T. Leukocyte-endothelial interactions in inflammation. J Cell Mol Med 2009; 13 (7) 1211-1220
26 Newman W, Beall LD, Carson CW , et al. Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock. J Immunol 1993; 150 (2) 644-654
27 Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14 (10) 506-512
28 Okajima K. Regulation of inflammatory responses by natural anticoagulants. Immunol Rev 2001; 184: 258-274
29 Okajima K, Harada N, Sakurai G , et al. Rapid assay for plasma soluble E-selectin predicts the development of acute respiratory distress syndrome in patients with systemic inflammatory response syndrome. Transl Res 2006; 148 (6) 295-300
30 Donnelly SC, Haslett C, Dransfield I , et al. Role of selectins in development of adult respiratory distress syndrome. Lancet 1994; 344 (8917) 215-219
31 Franchini M, Lippi G. Von Willebrand factor and thrombosis. Ann Hematol 2006; 85 (7) 415-423
32 Rubin DB, Wiener-Kronish JP, Murray JF , et al. Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. J Clin Invest 1990; 86 (2) 474-480
33 Ware LB, Conner ER, Matthay MA. von Willebrand factor antigen is an independent marker of poor outcome in patients with early acute lung injury. Crit Care Med 2001; 29 (12) 2325-2331
34 Bajaj MS, Tricomi SM. Plasma levels of the three endothelial-specific proteins von Willebrand factor, tissue factor pathway inhibitor, and thrombomodulin do not predict the development of acute respiratory distress syndrome. Intensive Care Med 1999; 25 (11) 1259-1266
35 Moss M, Ackerson L, Gillespie MK, Moore FA, Moore EE, Parsons PE. von Willebrand factor antigen levels are not predictive for the adult respiratory distress syndrome. Am J Respir Crit Care Med 1995; 151 (1) 15-20
36 Muller WA. Mechanisms of transendothelial migration of leukocytes. Circ Res 2009; 105 (3) 223-230
37 Conner ER, Ware LB, Modin G, Matthay MA. Elevated pulmonary edema fluid concentrations of soluble intercellular adhesion molecule-1 in patients with acute lung injury: biological and clinical significance. Chest 1999; 116 (1, Suppl): 83S-84S
38 McClintock D, Zhuo H, Wickersham N, Matthay MA, Ware LB. Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury. Crit Care 2008; 12 (2) R41
39 Flori HR, Ware LB, Glidden D, Matthay MA. Early elevation of plasma soluble intercellular adhesion molecule-1 in pediatric acute lung injury identifies patients at increased risk of death and prolonged mechanical ventilation. Pediatr Crit Care Med 2003; 4 (3) 315-321
40 Medford ARL, Millar AB. Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm?. Thorax 2006; 61 (7) 621-626
41 Ware LB, Kaner RJ, Crystal RG , et al. VEGF levels in the alveolar compartment do not distinguish between ARDS and hydrostatic pulmonary oedema. Eur Respir J 2005; 26 (1) 101-105
42 Wiener-Kronish JP, Albertine KH, Matthay MA. Differential responses of the endothelial and epithelial barriers of the lung in sheep to Escherichia coli endotoxin. J Clin Invest 1991; 88 (3) 864-875
43 Ware LB, Matthay MA. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 163 (6) 1376-1383
44 Lewis JF, Jobe AH. Surfactant and the adult respiratory distress syndrome. Am Rev Respir Dis 1993; 147 (1) 218-233
45 Kurahashi K, Kajikawa O, Sawa T , et al. Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J Clin Invest 1999; 104 (6) 743-750
46 Bitterman PB. Pathogenesis of fibrosis in acute lung injury. Am J Med 1992; 92 (6A) 39S-43S
47 Pastva AM, Wright JR, Williams KL. Immunomodulatory roles of surfactant proteins A and D: implications in lung disease. Proc Am Thorac Soc 2007; 4 (3) 252-257
48 Chroneos ZC, Sever-Chroneos Z, Shepherd VL. Pulmonary surfactant: an immunological perspective. Cell Physiol Biochem 2010; 25 (1) 13-26
49 Greene KE, Wright JR, Steinberg KP , et al. Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med 1999; 160 (6) 1843-1850
50 Greene KE, Ye S, Mason RJ, Parsons PE. Serum surfactant protein-A levels predict development of ARDS in at-risk patients. Chest 1999; 116 (1, Suppl): 90S-91S
51 Bersten AD, Hunt T, Nicholas TE, Doyle IR. Elevated plasma surfactant protein-B predicts development of acute respiratory distress syndrome in patients with acute respiratory failure. Am J Respir Crit Care Med 2001; 164 (4) 648-652
52 Shirasawa M, Fujiwara N, Hirabayashi S , et al. Receptor for advanced glycation end-products is a marker of type I lung alveolar cells. Genes Cells 2004; 9 (2) 165-174
53 Uchida T, Shirasawa M, Ware LB , et al. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med 2006; 173 (9) 1008-1015
54 Calfee CS, Budev MM, Matthay MA , et al. Plasma receptor for advanced glycation end-products predicts duration of ICU stay and mechanical ventilation in patients after lung transplantation. J Heart Lung Transplant 2007; 26 (7) 675-680
55 Broeckaert F, Bernard A. Clara cell secretory protein (CC16): characteristics and perspectives as lung peripheral biomarker. Clin Exp Allergy 2000; 30 (4) 469-475
56 Determann RM, Millo JL, Waddy S, Lutter R, Garrard CS, Schultz MJ. Plasma CC16 levels are associated with development of ALI/ARDS in patients with ventilator-associated pneumonia: a retrospective observational study. BMC Pulm Med 2009; 9: 49
57 Kropski JA, Fremont RD, Calfee CS, Ware LB. Clara cell protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury. Chest 2009; 135 (6) 1440-1447
58 The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342 (18) 1301-1308
59 Meduri GU, Headley S, Kohler G , et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 1995; 107 (4) 1062-1073
60 Park WY, Goodman RB, Steinberg KP , et al. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 164 (10 Pt 1) 1896-1903
61 Takala A, Jousela I, Takkunen O , et al. A prospective study of inflammation markers in patients at risk of indirect acute lung injury. Shock 2002; 17 (4) 252-257
62 Parsons PE, Moss M, Vannice JL, Moore EE, Moore FA, Repine JE. Circulating IL-1ra and IL-10 levels are increased but do not predict the development of acute respiratory distress syndrome in at-risk patients. Am J Respir Crit Care Med 1997; 155 (4) 1469-1473
63 Bouros D, Alexandrakis MG, Antoniou KM , et al. The clinical significance of serum and bronchoalveolar lavage inflammatory cytokines in patients at risk for Acute Respiratory Distress Syndrome. BMC Pulm Med 2004; 4: 6
64 Pittet JF, Mackersie RC, Martin TR, Matthay MA. Biological markers of acute lung injury: prognostic and pathogenetic significance. Am J Respir Crit Care Med 1997; 155 (4) 1187-1205
65 Suter PM, Suter S, Girardin E, Roux-Lombard P, Grau GE, Dayer JM. High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis 1992; 145 (5) 1016-1022
66 Donnelly SC, Strieter RM, Kunkel SL , et al. Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. Lancet 1993; 341 (8846) 643-647
67 Goodman RB, Strieter RM, Martin DP , et al. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 154 (3 Pt 1) 602-611
68 Cohen MJ, Brohi K, Calfee CS , et al. Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. Crit Care 2009; 13 (6) R174
69 Bastarache JA, Ware LB, Bernard GR. The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome. Semin Respir Crit Care Med 2006; 27 (4) 365-376
70 Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003; 285 (1) L20-L28
71 Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007; 35 (8) 1821-1828
72 Idell S, Koenig KB, Fair DS, Martin TR, McLarty J, Maunder RJ. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol 1991; 261 (4 Pt 1) L240-L248
73 Fuchs-Buder T, de Moerloose P, Ricou B , et al. Time course of procoagulant activity and D dimer in bronchoalveolar fluid of patients at risk for or with acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153 (1) 163-167
74 Günther A, Mosavi P, Heinemann S , et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161 (2 Pt 1) 454-462
75 Bastarache JA, Wang L, Geiser T , et al. The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. Thorax 2007; 62 (7) 608-616
76 Fremont RD, Koyama T, Calfee CS , et al. Acute lung injury in patients with traumatic injuries: utility of a panel of biomarkers for diagnosis and pathogenesis. J Trauma 2010; 68 (5) 1121-1127
77 Calfee CS, Ware LB, Glidden DV , et al; National Heart, Blood, and Lung Institute Acute Respiratory Distress Syndrome Network. Use of risk reclassification with multiple biomarkers improves mortality prediction in acute lung injury. Crit Care Med 2011; 39 (4) 711-717
78 Ware LB, Koyama T, Billheimer DD , et al; NHLBI ARDS Clinical Trials Network. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest 2010; 137 (2) 288-296
79 Lacy P. Metabolomics of sepsis-induced acute lung injury: a new approach for biomarkers. Am J Physiol Lung Cell Mol Physiol 2011; 300 (1) L1-L3
80 Stringer KA, Serkova NJ, Karnovsky A, Guire K, Paine III R, Standiford TJ. Metabolic consequences of sepsis-induced acute lung injury revealed by plasma ¹H-nuclear magnetic resonance quantitative metabolomics and computational analysis. Am J Physiol Lung Cell Mol Physiol 2011; 300 (1) L4-L11
81 Schnapp LM, Donohoe S, Chen J , et al. Mining the acute respiratory distress syndrome proteome: identification of the insulin-like growth factor (IGF)/IGF-binding protein-3 pathway in acute lung injury. Am J Pathol 2006; 169 (1) 86-95
82 de Torre C, Ying SX, Munson PJ, Meduri GU, Suffredini AF. Proteomic analysis of inflammatory biomarkers in bronchoalveolar lavage. Proteomics 2006; 6 (13) 3949-3957
83 Ware LB, Matthay MA. Beyond fishing: the role of discovery proteomics in mechanistic lung research. Am J Physiol Lung Cell Mol Physiol 2009; 296 (1) L12-L13
84 Christie JD, Wurfel MM, Feng R , et al; Trauma ALI SNP Consortium (TASC) investigators. Genome wide association identifies PPFIA1 as a candidate gene for acute lung injury risk following major trauma. PLoS ONE 2012; 7 (1) e28268
85 Howrylak JA, Dolinay T, Lucht L , et al. Discovery of the gene signature for acute lung injury in patients with sepsis. Physiol Genomics 2009; 37 (2) 133-139
86 Wang Z, Beach D, Su L, Zhai R, Christiani DC. A genome-wide expression analysis in blood identifies pre-elafin as a biomarker in ARDS. Am J Respir Cell Mol Biol 2008; 38 (6) 724-732
87 Wang Z, Chen F, Zhai R , et al. Plasma neutrophil elastase and elafin imbalance is associated with acute respiratory distress syndrome (ARDS) development. PLoS ONE 2009; 4 (2) e4380
88 Brun-Buisson C, Minelli C, Bertolini G , et al; ALIVE Study Group. Epidemiology and outcome of acute lung injury in European intensive care units. Results from the ALIVE study. Intensive Care Med 2004; 30 (1) 51-61
89 Matthay MA, Brower RG, Carson S , et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Randomized, placebo-controlled clinical trial of an aerosolized β₂-agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011; 184 (5) 561-568
90 Rice TW, Wheeler AP, Thompson BT, deBoisblanc BP, Steingrub J, Rock P. NIH NHLBI Acute Respiratory Distress Syndrome Network of Investigators. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. JAMA 2011; 306 (14) 1574-1581
91 Rice TW, Wheeler AP, Thompson BT , et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Initial trophic vs full enteral feeding in patients with acute lung injury: the EDEN randomized trial. JAMA 2012; 307 (8) 795-803
92 Brower RG, Lanken PN, MacIntyre N , et al; National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 2004; 351 (4) 327-336
93 Steinberg KP, Hudson LD, Goodman RB , et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006; 354 (16) 1671-1684
94 Wiedemann HP, Wheeler AP, Bernard GR , et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354 (24) 2564-2575
95 Ware LB. Prognostic determinants of acute respiratory distress syndrome in adults: impact on clinical trial design. Crit Care Med 2005; 33 (3, Suppl) S217-S222